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Embolism of cardiac origin accounts for about 20% of ischemic strokes. Nonvalvular atrial fibrillation is the most frequent cause of
cardioembolic stroke. Approximately 1% of population is aﬀected by atrial fibrillation, and its prevalence is growing with ageing in
the modern world. Strokes due to cardioembolism are in general severe and prone to early recurrence and have a higher long-term
risk of recurrence and mortality. Despite its enormous preventive potential, continuous oral anticoagulation is prescribed for less
than half of patients with atrial fibrillation who have risk factors for cardioembolism and no contraindications for anticoagulation.
Available evidence does not support routine immediate anticoagulation of acute cardioembolic stroke. Anticoagulation therapy’s
associated risk of hemorrhage and monitoring requirements have encouraged the investigation of alternative therapies for
individuals with atrial fibrillation. New anticoagulants being tested for prevention of stroke are low-molecular-weight heparins
(LMWH), unfractionated heparin, factor Xa inhibitors, or direct thrombin inhibitors like dabigatran etexilate and rivaroxaban.
The later exhibit stable pharmacokinetics obviating the need for coagulation monitoring or dose titration, and they lack clinically
significant food or drug interaction. Moreover, they oﬀer another potential that includes fixed dosing, oral administration, and
rapid onset of action. There are several concerns regarding potential harm, including an increased risk for hepatotoxicity, clinically
significant bleeding, and acute coronary events. Therefore, additional trials and postmarketing surveillance will be needed.
1. Introduction
Embolism of cardiac origin accounts for about 20% of
ischemic strokes. Several heart conditions enhance stroke
risk. Atrial fibrillation is the most common condition
of cardioembolic stroke, and anticoagulation is the treat-
ment generally indicated for secondary prevention and in
some cases for primary prevention. In this review, we
analyse cardiac conditions prone to cardioembolic infarct
and its management. We review atrial fibrillation, acute
myocardial infarct, congestive heart failure and dilated
cardiomyopathies, cardiac procedures, pacemakers, valve
diseases, and endocarditis. We provide a table with AHA
recommendations for patients with cardioembolic stroke
types (Table 1) [1]. Transesophageal echocardiography has
also provided evidence that the aortic arch is a common
source of embolic material, but the risk of cerebral embolism
appears to be directly related to the size of atherosclerotic
plaques visualized [2], so we have considered stroke due
to atherosclerosis in this entity. Most common localization
for cardioembolic stroke are total or partial areas supplied
by major arteries of anterior and posterior circulation,
most being cortical infarcts. Emboligenous cardiopathy, as
the only demonstrable etiology has been found in only
4% of lacunar infarctions [3], and its role as the etiol-
ogy of lacunar infarction is very rare [4]. Emboligenous
cardiopathy especially atrial fibrillation, rheumatic valve
disease, and nonbacterial thrombotic endocarditis have been
reported as very infrequent causes of lacunar infarction
in autopsy-based series [5]. Stroke and transient ischaemic
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attack (TIA) in terms of primary and secondary preven-
tion should be treated in the same way. We also review
antithrombotic treatment in special conditions and the new
anticoagulants which probably soon will replace the old
ones.
Oral anticoagulation (OAC) is the treatment of choice
for secondary prevention after a cardioembolic stroke [6, 7].
Warfarin is the commonest OAC used worldwide, although
acenocoumarol, phenprocoumon, or anisindione are fre-
quently prescribed in many countries. The mechanisms
of action of these OAC are comparable, as they inhibit
the vitamin K-dependent posttranslational carboxylation of
glutamate residues on the N-terminal regions of coagulation
factors II, VII, IX, and X by inhibiting the conversion of
vitamin 2, 3 epoxide to reduced vitamin K [8]. Although the
benefits of OAC are supported by a high degree of evidence
for stroke prevention in cardioembolic entities, such as
atrial fibrillation [8], they have a narrow therapeutic index,
numerous drug and dietary interactions, and a significant
risk of serious bleeding, including hemorrhagic stroke [9].
Alternatives to oral anticoagulation in this setting include
safer and easier to use antithrombotic drugs and definitive
treatment of atrial fibrillation.
2. Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac
arrhythmia, resulting in a prevalence of about 1% in the
general population [10]. The prevalence of atrial fibrillation
is strongly associated with increasing age, rising to 5% in
people older than 65 years and to nearly 10% in those aged
80 years [11]. AF is also the most frequent cardiac condition
associated to the risk of ischemic stroke, although it is only
weakly associated with transient ischemic attack (TIA) [12].
AF increases the risk of stroke 4- to 5-fold across all age
groups, accounting for 10% to 15% of all ischemic strokes
and nearly 25% of strokes in people older than 80 years [13,
14]. This translates to an incidence of stroke approximating
5% a year for primary events and 12% a year for recurrent
events [15]. In AF associated with rheumatic heart disease,
stroke risk is increased even more: 17-fold compared with
age-matched controls [16]. Patients with paroxysmal and
constant AF appear to have similar risks of stroke [17].
OAC therapy is highly eﬀective in reducing stroke in
patients with AF. In the late 1980s and early 1990s, 6
trials compared OAC therapy to placebo [17, 18]. Meta-
analysis showed that adjusted-dose oral anticoagulation
(target International Normalized Ratio (INR) 2.5; range, 2.0–
3.0) is highly eﬃcacious for prevention of all strokes (both
ischemic and hemorrhagic), with a risk reduction of 68%
(95% CI 50%–70%) as compared to placebo [13, 14, 19].
This reduction was similar for both primary and secondary
prevention and for both disabling and nondisabling strokes.
Aspirin showed a less consistent benefit for stroke prevention
than anticoagulation therapy. Aspirin compared to placebo
was evaluated in 3 trials, and a pooled analysis of these
studies showed a mean stroke risk reduction of 21% (95% CI
0%–38%) [20, 21]. Adjusted-dose OAC resulted in a relative
risk reduction of 52% (95% CI 37%–63%) compared to
aspirin [22].
In the Stroke Prevention in Atrial Fibrillation Trials
(SPAF I and II), which randomly assigned patients to
warfarin or aspirin (325mg per day), multivariate analysis
identified 4 atrial fibrillation subgroups with a substantial
stroke rate on aspirin: patients with systolic hypertension
(greater than 160), patients with impaired left ventricular
function, patients with a history of prior thromboembolism,
andwomen over 75 years in age [23]. Aspirin-treated patients
with 1 or more of these risk factors had a thromboembolic
rate of about 6% per year whereas those without these risk
factors had a thromboembolic rate of about 2% per year.
In the SPAF Trial II, the combined use of fixed-dose
warfarin (mean daily dose = 2.1mg) with aspirin (325mg
per day) was tested as an alternative therapy to adjusted-dose
warfarin (target international normalized ratio of 2.0 to 3.0)
in patients with at least 1 risk factor for stroke as identified in
the previous analyses [24]. The trial was stopped early when
the rate of embolismwas discovered to be significantly higher
in the patients on the combination therapy (7.9% per year)
as compared to those on adjusted-dose warfarin (1.9% per
year). A meta-analysis of randomized trials comparing OAC
with combined aspirin and anticoagulation at the same target
INR showed an increased risk of bleeding in the combined
therapy arm (odds ratio 1.43, 95% CI 1.00 to 2.02) [25].
The adequacy of aspirin prophylaxis was evaluated in Stroke
Prevention in Atrial Fibrillation Trial III among patients
without any of the 4 identified stroke risk factors. Stroke or
systemic embolism occurred at a rate of 2.2% per year among
patients taking aspirin [26]. The annual rate of stroke or
systemic embolism was significantly higher in patients with a
history of hypertension (more than 140mmHg but less than
160mmHg systolic) than in those without.
The ACTIVE W trial (Atrial fibrillation Clopidogrel Trial
with Irbesartan for prevention of Vascular Events), which
compared the eﬃcacy of combined antiplatelet therapy
(aspirin 75 to 100mg and clopidogrel 75mg) versus OAC
in high-risk patients with AF, demonstrated clearly the
superiority of OAC in the long-term prevention of major
ischemic events and had a similar bleeding rate [27]. In the
ACTIVE A trial, 7554 patients with AF who were considered
unsuitable to receive vitamin-K antagonist therapy were
randomized to receive clopidogrel (75mg/day) or placebo
added to aspirin. The addition of clopidogrel to aspirin
reduced the rate of major vascular events from 7.6% per year
to 6.8%, primarily due to a reduction in the rate of stroke
[28]. However, the rate of major hemorrhage increased from
1.3% to 2.0% per year.
Experts conclude that warfarin therapy is indicated when
the risk of stroke is high, and that aspirin is preferred
when the risk of stroke is low. Several attempts have been
made to establish and validate risk stratification schemes
to quantify the absolute risk of stroke in patients with
nonvalvular atrial fibrillation [29, 30] (Table 2). A systematic
review was conducted to identify independent risk factors
for stroke in patients who have AF [31]. There are 4 most
consistent independent factors for stroke: prior stroke or
transient ischemic attack (relative risk 2.5, 95%CI 1.8 to 3.5),
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Table 1: Recommendations for patients with cardioembolic stroke types (AHA Guideline 2006).
Risk factor Recommendation
Level of
evidence
AF
For patients with ischemic stroke or TIA with persistent or paroxysmal (intermittent) AF,
anticoagulation with adjusted-dose warfarin (target INR, 2.5; range, 2.0-3.0) is recommended.
Class I,
Level A
In patients unable to take oral anticoagulants, aspirin 325mg/d is recommended.
Class I,
Level A
Acute MI and LV
thrombus
For patients with an ischemic stroke caused by an acute MI in whom LV mural thrombus is identified
by echocardiography or another form of cardiac imaging, oral anticoagulation is reasonable, aiming for
an INR of 2.0 to 3.0 for at least 3mo and up to 1 y.
Class IIa,
Level B
Aspirin should be used concurrently for the ischemic CAD patient during oral anticoagulant therapy in
doses up to 162 mg/d, preferably in the enteric-coated form.
Class IIa,
Level A
Cardiomyopathy
For patients with ischemic stroke or TIA who have dilated cardiomyopathy, either warfarin (INR, 2.0 to
3.0) or antiplatelet therapy may be considered for prevention of recurrent events.
Class IIb,
Level C
Rheumatic mitral
valve disease
For patients with ischemic stroke or TIA who have rheumatic mitral valve disease, whether or not AF is
present, long-term warfarin therapy is reasonable, with a target INR of 2.5 (range, 2.0-3.0).
Class IIa,
Level C
Antiplatelet agents should not be routinely added to warfarin in the interest of avoiding additional
bleeding risk.
Class III,
Level C
For ischemic stroke or TIA patients with rheumatic mitral valve disease, whether or not AF is present,
who have a recurrent embolism while receiving warfarin, adding aspirin (81mg/d) is suggested.
Class IIa,
Level C
Mitral valve
prolapse
For patients with MVP who have ischemic stroke or TIAs, long-term antiplatelet therapy is reasonable.
Class IIa,
Level C
Mitral annular
calcification
Patients with ischemic stroke or TIA and MAC not documented to be calcific antiplatelet therapy may
be considered.
Class IIb,
Level C
Among patients with mitral regurgitation resulting from MAC without AF, antiplatelet or warfarin
therapy may be considered.
Class IIb,
Level C
Aortic valve disease
For patients with ischemic stroke or TIA and aortic valve disease who do not have AF, antiplatelet
therapy may be considered.
Class IIa,
Level C
Prosthetic heart
valves
For patients with ischemic stroke or TIA who have modern mechanical prosthetic heart valves, oral
anticoagulants are recommended, with an INR target of 3.0 (range, 2.5–3.5).
Class I,
Level B
For patients with mechanical prosthetic heart valves who have an ischemic stroke or systemic embolism
despite adequate therapy with oral anticoagulants, aspirin 75 to 100mg/d, in addition to oral
anticoagulants, and maintenance of the INR at a target of 3.0 (range, 2.5–3.5) are reasonable.
Class IIa,
Level B
For patients with ischemic stroke or TIA who have bioprosthetic heart valves with no other source of
thromboembolism, anticoagulation with warfarin (INR, 2.0–3.0) may be considered.
Class IIb,
Level C
Patent foramen
ovale
For patients with an ischemic stroke or TIA and a PFO, antiplatelet therapy is reasonable to prevent a
recurrent event.
Class IIa,
Level B
Warfarin is reasonable for high-risk patients who have other indications for oral anticoagulation such
as those with an underlying hypercoagulable state or evidence of venous thrombosis.
Class IIa,
Level C
Insuﬃcient data exist to make a recommendation about PFO closure in patients with a first stroke and
a PFO. PFO closure may be considered for patients with recurrent cryptogenic stroke despite medical
therapy.
Class IIb,
Level C
hypertension (relative risk 2.0, 95% CI 1.6 to 2.5), diabetes
mellitus (relative risk 1.7, 95% CI 1.4 to 2.0), and increasing
age (relative risk 1.5, 95% CI 1.3 to 1.7). The absolute rates of
stroke in patients with only 1 independent risk are 6% to 9%
per year for history of stroke/transient ischemic attack, 2%
to 3.5% per year for diabetes mellitus, and 1.5% to 3% per
year for both hypertension and age of more than 75 years.
However, there is no conclusive evidence that congestive
heart failure and coronary artery disease are independent risk
factors for stroke.
The HEMORR2HAGES scheme was developed by com-
bining bleeding risk factors from previous schemes and
validated to quantify the risk of bleeding in anticoagulated
patients [35]. The scheme is calculated by adding 1 point
for each of the following factors: hepatic or renal disease,
ethanol abuse, malignancy, old age (older than 75 years),
reduced platelet counts or platelet dysfunction, uncontrolled
hypertension, anemia, genetic factors, elevated fall risk,
stroke, and 2 points for rebleeding (Table 3).
In primary prevention studies OAC lowered the mortal-
ity rate by 33% (95% CI 9%–51%), and the combined out-
come of stroke, systemic embolism, and death by 48% (95%
CI 34%–60%) [15]. In these studies, the reported annual
incidence of major bleeding and intracranial hemorrhage
was 1.3% and 0.3% in anticoagulated patients, compared to
1% and 0.1% in control patients. The risk of intracranial
hemorrhage is significantly increased at INR values >4.0,
with increasing age, and in patients with a history of stroke
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Table 2: Stroke risk stratifications schemes in patients with nonvalvular atrial fibrillation (BP: blood pressure, DM: diabetes mellitus, CHF:
congestive heart failure, TIA: transient ischemic attack, CAD: coronary artery disease, LV: left ventricular fractional shortening).
Scheme Low risk Moderate risk High risk
AFI [7] Not moderate/high risk Age > 65, not high risk
Prior ischemia, high BP,
DM
SPAF [32] Not moderate/high risk High BP, not high risk
Prior ischemia, female
>75 yrs, CHF, LV <25%,
systolic BP > 160
ACCP [10, 33] Not moderate/high risk
1 of the following:
65–75 yrs, DM, CAD, and
not high risk
Prior ischemia, high BP,
CHF, >75 yrs, or ≥2
moderate risk factors
CHADS2 [14] SCORE = +1 for CHF, high BP, DM, >75 yr, and +2 for prior stroke/TIA
FRAMINGHAM [34] SCORE = +6 for prior ischemia, 0 to 4 for BP, +4 for DM, +0 to 10 for age, 6 for female
Table 3: Incidence of major bleeding stratified by the HEMORR2HAGES score (data from the National Registry of Atrial Fibrillation).
HEMORR2HAGES store No. of patients No. of bleeding Bleeding per 100 patient-years warfarin (95% CI)
0 209 4 1.9 (0.6–4.4)
1 508 11 2.5 (1.3–4.3)
2 454 20 5.3 (3.4–8.1)
3 240 15 8.4 (4.9–13.6)
4 106 9 10.4 (5.1–18.9)
≥5 87 8 12.3 (5.8–23.1)
Any score 1604 67 4.9 (3.9–6.3)
[36]. From the available information it is clear that oral
anticoagulation is more eﬃcacious and more risky than
aspirin to prevent first stroke in patients with AF [7]. Chronic
oral anticoagulation therapy is indicated in patients with AF
and high risk of stroke unless contraindicated [10, 37]. The
optimal intensity of anticoagulation for prevention of stroke
in atrial fibrillation patients appears to be an international
normalized ratio of 2.0 to 3.0, with a target of 2.5. A case-
control study found that the eﬃcacy of warfarin declines
sharply below an international normalized ratio of 2.0 [38],
and the risk of major hemorrhage appears to increase
significantly above an international normalized ratio of 3.0
to 4.0.
Despite the encouraging results of OAC in AF, this
treatment is underutilized in clinical practice as more than
one-third of eligible patients in primary care practice are not
receiving it [39], and subtherapeutic INR are encountered in
45% of patients taking OAC [40].
Current guidelines for antithrombotic therapy are based
on the absolute risk for stroke balanced with the estimated
bleeding risk [10, 37]. In brief, if (1) no risk factors for
stroke: aspirin therapy (81 to 325mg daily); (2) 1 moderate
risk factor for stroke (age over 75 years, high blood pressure,
heart failure, impaired left ventricular systolic function with
an ejection fraction of 35% or less, or diabetes): aspirin (81
to 325mg) or warfarin (international normalization ratio 2.0
to 3.0, target 2.5); (3) more than 1moderate, or any high-risk
factor for stroke (previous stroke, transient ischemic attack,
systematic embolism, or prosthetic heart valve): warfarin
(international normalization ratio 2.0 to 3.0, target 2.5; in
case of amechanical valve, target international normalization
ratio is greater than 2.5) [10]. Alternative recommendations
use the CHADS2 scheme for risk stratification [29, 37].
Stroke-prone patients are reliably identified by a CHADS(2)
score >3, and they have an average risk of 5.5 strokes per
100 patient-years on aspirin [41]. The CHADS2 scheme is
comprised of 5 conditions: recent congestive heart failure,
hypertension, age of 75 years or older, and diabetes (each
of which accounts for 1 point) as well as prior stroke or
transient ischemic attack, which accounts for 2 points in total
score calculation (Table 4).
To date, there are no randomized trials to determine the
eﬃcacy of anticoagulation treatment for diﬀerent subtypes of
stroke. However, there is a recommended treatment strategy
for patients with atrial fibrillation presenting with stroke
or transient ischemic attack [42]. In a large, multicenter,
randomized study comparing rhythm- with rate-control
strategy in patients with atrial fibrillation and high risk of
stroke or death, rhythm-control strategy oﬀered no survival
advantage. Attempted maintenance of sinus rhythm did
not reduce the risk of ischemic stroke [43]. The eﬀect
of the intensity of oral anticoagulation on the severity of
atrial fibrillation-related stroke was assessed [44]. Adequate
anticoagulation reduced not only the frequency of ischemic
stroke but also its severity and the risk of death from
stroke, highlighting an important incremental benefit of
anticoagulation.
Despite its proven eﬃcacy in secondary prevention of
stroke, anticoagulation therapy is not initiated in a major
portion of especially elderly patients with AF, mainly because
of contraindications but also because of multiple patient and
physician barriers [29]. There has been some concern about
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Table 4: CHADS2 score quantification of stroke risk for patients with atrial fibrillation. NRAF: National Registry of Atrial Fibrillation. From
[25].
CHADS2 score
No. of patients
(n = 1733)
No. of stroke
(n = 94)
NRAF crude stroke rate per
100 patient-years
NRAF adjusted stroke rate
(95% CI)
0 120 2 1.2 1.9 (1.2 to 3.0)
1 463 17 2.8 2.8 (2.0 to 3.8)
2 523 23 3.6 4.0 (3.1 to 5.1)
3 337 25 6.4 5.9 (4.6 to 7.3)
4 220 19 8.0 8.5 (6.3 to 11.1)
5 65 6 7.7 12.5 (8.2 to 17.5)
6 5 2 44.0 18.2 (10.5 to 27.4)
the risk/benefit of oral anticoagulation in elderly patients,
because of a greater risk of hemorrhagic complications in this
group of patients. However, the WASPO (Warfarin versus
Aspirin for Stroke Prevention in Octogenarians) [45] and
BAFTA (Birmingham Atrial Fibrillation Treatment of the
Aged) trials [46] have shown that OAC is safe and eﬀective in
older individuals. Therefore, there is no justification to avoid
anticoagulation in very old individuals with AF, unless there
is a clear contraindication.
3. Acute Myocardial Infarction
Stroke is a rare but feared complication of acute myocardial
infarction (AMI) [47] that can complicate the course and
outcome of those patients. The incidence of stroke during
the acute phase following myocardial infarction varies
considerably between studies. Rates are mostly in the range
of 0.8% to 3.2%, approximately one-third occur within 24
hours following admission whereas about two-thirds occur
in the first week after the myocardial infarction [48, 49].
Advanced age and AF are associated with higher risk of
stroke [50, 51]. Late stroke following myocardial infarction
is rare, although patients are still at increased risk during
the first 1 to 2 months. The risk for stroke remained 2- to
3-times higher than expected during the first 3 years after
myocardial infarction [52]. A case-control study showed that
stroke secondary to AMI causes a severer neurological deficit,
more unfavorable clinical course, and higher mortality than
stroke in patients without a recent AMI [53]. Most ischemic
strokes after AMI involve the anterior circulation and are
nonlacunar [54]. Posterior circulation strokes are unusual.
Etiology of stroke after AMI can be ascribed to a com-
mon pathophysiologic process: atherosclerosis; formation
of mural thrombi in areas of ventricular hypokinesis after
myocardial damage and AF and cardioversion [50]. Strokes
occurring several weeks after AMI may be due to chronic left
ventricular thrombi, an akinetic left ventricular segment, or
left ventricular dysfunction. Indeed, cerebral microembolism
was detected by transcranial Doppler more often among
patients with AMI with reduced left ventricular function,
akinetic segments, or left ventricular thrombi [54]. For
every decrease of 5% in the ejection fraction, an 18%
increase in the risk of long-term stroke has been found
[55]. Inflammatory changes at the endocardial surface also
enhance thrombogenicity. A systemic hypercoagulable state
may promote thromboembolism early after the coronary
event whereas residual fresh thrombus may enhance coag-
ulation during the first 1 to 3 months.
Thrombolytic therapy carries a small but significant risk
of intracranial hemorrhage [56–58] but the overall risk of
stroke due to thrombolytic therapy in properly selected AMI
patients is low compared with the impressive reduction in
mortality and, thus, is associated with a favorable benefit-risk
profile. Early coronary revascularization diminishes the risk
of ischemic stroke with acute myocardial infarction. A delay
in the acute revascularization of these patients influences the
risk of perimyocardial infarction ischemic stroke indepen-
dent of size of infarction or residual ventricular function
[59].
Anticoagulation with full-dose heparin decreases the risk
of left ventricular thrombi in patients with anterior AMI
and may be eﬀective in reducing the risk of embolization
in those with left ventricular thrombi. Aspirin reduced the
risk of early ischemic stroke by half in the ISIS-2 mega-trial
[60]. Long-term oral anticoagulant treatment in survivors
of myocardial infarction has been shown to reduce the
frequency of stroke by 40% to 50% over a 3-year period
[55, 61]. In patients, after AMI, anticoagulation therapy
is indicated for embolic stroke prevention, and antiplatelet
therapy is a matter of ongoing investigation [62, 63]. The
risk of recurrent myocardial infarction, stroke, or death was
significantly reduced by OAC compared to aspirin therapy
in one study that allocated the antithrombotic regimens
within 8 weeks of AMI or unstable angina [64]. Aspirin with
medium-intensity OAC was also more eﬀective than aspirin
on its own in reduction of subsequent cardiovascular events
and death. Therefore, it is recommended that OAC should be
taken long term, or for at least 3 months after cardioembolic
stroke due to AMI [65].
Following an acute cardioembolic stroke due to left
ventricular thrombi, risk for a recurrent early embolic event
is high. To decide when to start anticoagulant treatment, one
has to balance the benefit of reduction in early recurrent
embolism against the risk of potentiating secondary brain
hemorrhage. Cardioembolic strokes have a propensity for
secondary hemorrhagic transformation and, therefore, no
consensus has been reached on the optimum strategy.
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A greater availability of primary angioplasty should
decrease stroke rates, and the introduction of newer throm-
bolytic agents, weight-adjusted administration of heparin,
low-molecular weight heparins, and a new generation of
antiplatelet drugs such as the glycoprotein IIb/IIIa receptor
antagonists may also aﬀect stroke rates as well as deter-
minants of intracranial hemorrhage in patients with AMI
[66].
4. Congestive Heart Failure
Congestive heart failure aﬀects 4.7 million people in the
United States [67]. The number of people who have had
congestive heart failure is increasing, and clinical trials are
trying to evaluate the optimal strategy for stroke prevention
in this group. As the population ages and cardiac care
improves, there is a growing number of patients living
with reduced cardiac ejection fraction. The incidence of
thromboembolism secondary to congestive heart failure
(CHF) varies depending on the prospective or retrospective
design of the studies, and whether clinical or autopsy data
are assessed. Prospective studies of patients with dilated
cardiomyopathy have reported a stroke incidence of 1.7 per
100 patient-years [68] while retrospective studies have given
an incidence of 3.5 symptomatic events per 100 patient-years
[69]. Certain groups of patients with CHF have well defined
indications for chronic anticoagulation, such as previous
thromboembolic event, AF, or the presence of newly formed
left ventricular thrombus [70, 71]. But generally, evidence
from published reports does not demonstrate convincingly
that the benefits of OAC exceed the risks. The SAVE [55]
and SOLVD [72] databases have shown that low-dose aspirin
may be useful in preventing thromboembolism and may be
less risky than OAC. In patients with underlying coronary
artery disease, aspirin probably confers additional benefit.
In the SAVE trial [55], aspirin use significantly reduced the
risk of stroke by 56%, and the protective eﬀect of aspirin was
most pronounced in patients with a left ventricular ejection
fraction <28%; in this group, aspirin use was associated
with a reduction in risk of stroke of 66% (P < .001).
Similarly, the SOLVD trial [72] showed a beneficial eﬀect
of aspirin, especially in women. The use of antiplatelet
agents was associated with a 23% reduction in the risk of
embolism in men and 53% reduction in women. Aspirin
was also associated with a 24% reduction in the risk
of sudden death [72]. The Warfarin Antiplatelet Trial in
Chronic Heart Failure was designed to compare warfarin,
aspirin, and clopidogrel. However, it was terminated early
due to poor enrollment. Another study, “Warfarin versus
Aspirin in Reduced Cardiac Ejection Fraction,” is in progress
and will examine the role of warfarin versus aspirin in the
primary and secondary prevention of stroke in patients with
a reduced ejection fraction of less than 30% [73].
5. Valvular Heart Diseases
5.1. Rheumatic Mitral Valve Disease. Mitral valve steno-
sis (MS) is usually a sequela of rheumatic fever, which
aﬄicts approximately 1.5 million Americans. Mitral steno-
sis causes the left atrium to dilate and is a frequent
cause of atrial fibrillation. A left atrial thrombus forms
in a large number of aﬀected patients and provides the
substrate for cerebral embolism [74]. Embolism may also
occur in mixed lesions of the mitral valve (stenosis-
regurgitation), but isolated mitral regurgitation is not a
common cause of cerebral embolism. Aortic stenosis is
a rare cause of cerebral emboli, which are usually cal-
cific.
Recurrent embolism occurs in 30 to 65% of patients
with rheumatic mitral valve disease, 60 to 65% during
the first year, and most within 6 months. The risk of
embolization is related to age and the presence of AF [74–
78]. Retrospective studies have shown a 4- to 15-fold decrease
in the incidence of embolic events with anticoagulation in
these patients [77, 79]. This benefit applies to both systemic
and pulmonary embolism. Most trials involved patients who
had 1 embolus before the onset of anticoagulation therapy
[79]. However, large randomized trials have demonstrated
a significant reduction in embolic events by treatment with
anticoagulation in subsets of patients with AF not associated
with MS [80, 81]. In these randomized trials, the subset of
patients who benefitedmost from anticoagulation were those
with the highest risk of embolic events [82, 83]. Patients
with MS at the highest risk for future embolic events are
those with prior embolic events and those with paroxysmal
or persistent AF [76–79, 84, 85]. There are no data to support
the concept that OAC is beneficial in patients with MS who
have not had AF or an embolic event [86, 87]. Exceptions to
OAC include pregnant women or the patient at high risk for
serious bleeding [88]. In patients with recurrent embolism
despite being treated with OAC at a therapeutic INR, it is
recommended to add aspirin (75–100mg/d), dipyridamole
(400mg/d), or clopidogrel (75mg/d) [88].
5.2. Mechanical Prosthetic Heart Valves. It is well established
that patients with all types of mechanical valves require
antithrombotic prophylaxis for stroke prevention [89]. Lack
of prophylaxis in patients with St. Jude Medical bileaflet
valves was associated to embolism or valve thrombosis in
12% per year with aortic valves, and 22% per year withmitral
valves [90]. For mechanical prostheses in the aortic posi-
tion, the INR with warfarin therapy should be maintained
between 2.0 and 3.0 for bileaflet valves and medtronic Hall
valves and between 2.5 and 3.5 for other disc valves and
Starr-Edwards valves; or prostheses in the mitral position,
the INR should be maintained between 2.5 and 3.5 for all
mechanical valves [89, 91]. The recommendation for higher
INR values in the mitral position is based on the greater risk
of thromboembolic complications with mechanical valves
in the mitral position [89, 92–98] and the greater risk of
bleeding to higher INRs [97]. In patients with aorticmechan-
ical prosthesis who are at higher risk of thromboembolic
complications, INR should be maintained at 2.5 to 3.5,
and the addition of aspirin should be considered. These
include patients with AF, previous thromboembolism, and
a hypercoagulable state. Many would also include patients
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with severe left ventricular (LV) dysfunction in this higher-
risk group [99]. In older devices, such as caged ball or caged
disk valve, the optimal INR for thromboembolic prevention
has be to higher, from 4.0 to 4.9 [94]. The combination
of OAC and aspirin may be particularly useful in patients
with prosthetic valves who have coronary artery disease or
stroke [100]. Available data suggest that neither adjusted-
dose unfractionated heparin nor fixed-dose low-molecular
weight heparin (LMWH) provide adequate protection in
pregnant patients with mechanical heart valves [88].
5.3. Bioprosthetic Heart Valves. In patients with biopros-
thetic valves without AF, long-term therapy with aspirin
(75–100mg/d) is recommended [6, 89]. For patients with
bioprosthetic valves in the mitral position OAC with a
target INR from 2.0 to 3.0 is recommended during the first
3 months after valve insertion [88]. On the other hand,
patients with bioprosthetic valves in the aortic position can
be given either OAC (INR 2.0-3.0) or aspirin (80–100mg/d)
during the first 3 months after valve insertion [88]. In
the remaining patients with associated risk factors for
thromboembolism, such as AF, previous thromboembolism,
or hypercoagulable condition, lifelong warfarin therapy is
indicated to achieve an INR of 2.0 to 3.0. Many would
also recommend continuing anticoagulation in patients with
severe LV dysfunction (ejection fraction less than 30%) [99].
5.4. Mitral Annular Calcification and Aortic Valve Sclerosis.
Mitral annular calcification is characterized by calcium and
lipid deposition in the annular fibrosa of the mitral valve
whereas aortic valve sclerosis results from similar accu-
mulation involving the aortic valve leaflets. Mitral annular
calcification and aortic valve sclerosis are associated with
atherosclerosis risk factors that can promote left ventricular
hypertrophy and left atrial enlargement, each of which
has been reported to predict cerebrovascular events. The
American College of Chest Physicians (ACCP) recommends
long-term OAC in patients with mitral annular calcification
complicated by systemic embolism not documented to be
calcific embolism [88]. For patients with repeated embolic
events despite anticoagulation therapy, or in whom multiple
calcific emboli are recognized, valve replacement should be
considered.
5.5. Mitral Valve Prolapse. The prevalence of mitral valve
prolapse (MVP) in community-based studies is low (2.4%),
and no more common among young patients with unex-
plained cerebral embolic events [101]. Utilizing current
echocardiographic criteria for diagnosing MVP (valve pro-
lapse of 2mm or more above the mitral annulus in
the long-axis parasternal view and other views [102], the
prevalence of this entity is 1% to 2.5% of the population
[103]. MVP occurs as a clinical entity with or without
thickening (5mm or greater, measured during diastasis)
and with or without mitral regurgitation. Primary MVP
can be familial or nonfamilial. Daily aspirin therapy (75
to 325mg per day) is recommended for MVP patients
with documented transient focal neurological events who
are in sinus rhythm with no trial thrombi. Such patients
also should avoid cigarettes and oral contraceptives. The
American Stroke Association guidelines [104] recommend
aspirin for patients with MVP who have experienced an
ischemic stroke (class IIa, level of evidence C), based on the
evidence of eﬃcacy of antiplatelet agents for general stroke
patients. No randomized trials have addressed the eﬃcacy of
selected antithrombotic therapies for the specific subgroup
of stroke patients with MVP. In the current guidelines, the
committee recommends aspirin for those poststroke patients
with MVP who have no evidence of mitral regurgitation,
AF, left atrial thrombus, or echocardiographic evidence of
thickening (5mm or greater) or redundancy of the valve
leaflets. However, long-term anticoagulation therapy with
warfarin is recommended (class I) for poststroke patients
with MVP who have mitral regurgitation, AF, or left atrial
thrombus. In the absence of these indications, warfarin is
also recommended (class IIa) in poststroke patients with
MVP who have echocardiographic evidence of thickening
(5mm or greater) or redundancy of the valve leaflets
and in MVP patients who experience recurrent TIA while
taking aspirin. In each of these situations, INR should
be maintained between (2.0 and 3.0). In MVP patients
with AF, warfarin therapy is indicated in patients aged
greater than 65 years and in those with mitral regurgitation,
hypertension, or a history of heart failure (INR 2.0 to 3.0)
[105, 106]. Daily aspirin therapy is often recommended
for patients with high-risk echocardiographic characteristics.
Nevertheless, it is recommended that patients with MVP and
stroke receive antithrombotic therapy if alternative causes of
brain ischemia cannot be identified [88].
6. Cardiac Procedures
The number of patients undergoing cardiac revasculariza-
tion procedures is ever increasing. Technological as well
as surgical and anesthesiological advances have reduced
the mortality and morbidity associated with these cardiac
procedures. Neurologic complications are the leading cause
of morbidity after cardiac operations.
6.1. Cerebrovascular Complications of Coronary Artery Bypass
Surgery. The incidence of strokes after coronary artery
bypass surgery has been reported variably depending on
whether the study is retrospective or prospective; 1.5%
to 5.2% in prospective studies [107–109]. Using highly
sensitive diﬀusion-weighted MRI increases the incidence of
cerebral infarctions to 18%. However, about two-thirds of
these are asymptomatic [110]. Several pathophysiological
mechanisms likely play a role in the causation of neuro-
logic complications following cardiac surgery. Mechanical,
thermal, hemodynamic, metabolic, infectious, and pharma-
cologic factors are all likely. Pathological studies of brains
of patients who died after cardiac surgery reveal dilation of
small capillaries and arterioles often at bifurcations. Staining
with oil red O and osmium have revealed these to be due to
fat microemboli numbering in the thousands. Atheromatous
debris is also responsible for brain embolism during and
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after cardiac surgery especially in patients with severe
aortic atherosclerosis [111]; coronary bypass surgery without
cardiopulmonary bypass (oﬀ-pump CABG) is theoretically
associated with a lower risk of stroke, given its advantages
of no aortic manipulation, no hypothermia, and no use of
the cardiopulmonary bypass pump [112]. In a large study
with 16,184 patients the incidence of stroke was lower in
the oﬀ-pump group (2.5%) compared to the conventional
CABG group (3.9%) [113]. Embolism has been implicated in
the pathophysiology of stroke after on-pump CABG whereas
myocardial stunning and hypoperfusion may be possible
mechanisms associated with delayed onset of stroke after oﬀ-
pump CABG [112]. The timely administration of platelet
inhibitors and/or per-operative anticoagulation, as well as
prevention of hypotensive episodes may be indicated in oﬀ-
pump CABG as preventive measures against delayed onset
of stroke. Yet, further studies are needed to prospectively
investigate the potential benefits of pharmaceutical agents in
reducing the incidence of stroke after CABG.
6.2. Cerebrovascular Complications of Left-Sided Cardiac
Catheterization. Almost two-thirds of all coronary revas-
cularization procedures are catheter-based percutaneous
coronary interventions. Its frequency is growing whereas
that of coronary artery bypass graft is declining relatively.
Clinically relevant embolic events during diagnostic car-
diac catheterization occur in 0.1% to 0.4% of patients
[114]. Stroke was significantly associated with the severity
of coronary artery disease (perhaps an indication of the
atherosclerotic burden) and the duration of the procedure.
Moreover, many embolic events occur that remain clinically
silent as evidenced by the prospective study of Bu¨sing and
colleagues [115]. Using diﬀusion-weighted MRI studies,
15% of individuals undergoing cardiac catheterization were
shown to have abnormalities indicating cerebral infarcts
although they were clinically asymptomatic.
Stroke is a rare but dramatic complication of invasive
cardiac procedures. In contrast to noniatrogenic stroke, the
situation in a catheterization laboratory is unique because
arterial access is already available and thrombolytic therapy
potentially can be initiated without delay, often through
the same catheter [116]. Besides intra-arterial thrombolysis,
mechanical clot retrieval is also possible. Typically, patients
who are preparing for cardiac transplantation are immedi-
ately anticoagulated after the implant of the left ventricular
assist devices [117].
6.3. Cerebrovascular Complications of Cardiac Transplanta-
tion. Neurologic complications in heart transplant recipi-
ents in the modern era occur at a rate of 7% to 23%. Cere-
brovascular complications include ischemic stroke, transient
ischemic attacks, and cerebral hemorrhage. Transplantation-
associated ischemic stroke is significantly more common in
patients transplanted for dilated cardiomyopathy or in those
with a history of prior stroke [32, 33].Most neurologic events
after heart surgery occur in a subset of patients who can be
identified before the operation. In the studies by Riccotta and
colleagues, 4 factors have been associated with the risk of
stroke: (1) carotid stenosis greater than 50%, (2) repeat heart
surgery, (3) valve surgery, and (4) prior stroke [34, 118].
Elderly patients and women represent a strong demographic
risk factor for adverse neurologic events.
7. Pacemakers
Pacemakers are needed to treat many cardiac conditions, but
its presence may make the diagnosis of AF diﬃcult. Indeed,
many patients with pacemakers develop AF, and some
patients with AF have concomitant sinus node dysfunction,
thus requiring the use of pacemakers [119]. The lack of
diagnose of AF may lead to the omission of appropriate
treatment with OAC. Thus, patients with AF after pacemaker
implantation may have a 70% higher relative risk of stroke
than patients without AF, even after adjustment for impor-
tant clinical predictors [120]. Patients on pacemakers for
sinus node dysfunction had an actuarial incidence of stroke
of 3% at one year, and 5% at five years, and 13% at 10 years
[121]. Pacemakers have diﬀerentmodes of programming and
stimulation, and the incidence of AF and embolism may
diﬀer accordingly.
8. Patent Foramen Ovale (PFO)
In a significant proportion of the general population there
are various forms of interatrial communication, such as
patent foramen ovale, atrial septal defect, and associated
disorders such as atrial septal aneurysm (ASA). Several
authors have associated these disorders with paradoxical
embolic phenomena and cryptogenic strokes as well as
diﬀerent other pathologies as migraines with aura, transient
global amnesia, or the presence of “multiple ischemic brain
lesions” in divers for example [122–128]. Other studies and
expert opinions question these associations and emphasize
that these interatrial communications are for the most part
innocent bystanders [129–133]. In the Stroke Prevention:
Assessment of Risk in a Community (SPARC) echocardio-
graphy study [132], PFO was not a significant independent
predictor of stroke (HR 1.46, 95% CI 0.74 to 2.88). The
secondary stroke prevention in patients with PFO has been
evaluated in several studies. In the PFOASA (Patent Foramen
Ovale-Atrial Septum Aneurysm) study, young patients (from
18 to 55 years) with cryptogenic stroke within the preceding 3
months were prospectively followed during 4 years of aspirin
therapy (300 mg per day) [134]. The risk of recurrent stroke
was 2.3% in patients with PFO alone, 15.2% among patients
with both PFO and ASA, 4.2% among patients with neither
of these cardiac abnormalities, and 0% in patients with ASA
alone.
Given its prevalence in about a quarter of the normal
population and that the estimated yearly risk of cryptogenic
stroke in healthy people is as low as 0.1% [135], treatment
in any manner because of the mere presence of an incidental
PFO is unnecessary. Medical options (use of antiplatelets or
anticoagulation) and surgical options (open surgical closure,
minimally invasive surgery, and percutaneous devices) [136]
are available for the treatment of patients after they have
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suﬀered a cryptogenic stroke as secondary prevention. The
choice of therapy depends especially on the clinical settings
in which the stroke occurred (antecedent Valsalva maneuver,
hypercoagulable state, and multiple strokes or events) and
the morphological characteristics of the PFO (large opening,
large right-to-left shunting (RLSh), RLSh at rest, and the
presence of an ASA [137, 138], but making the choice
of treatment modalities, especially the surgical options, is
controversial. To date there are no published data on studies
that have randomly assigned patients with cryptogenic stroke
and PFO to diﬀerent therapies. The studies so far have been
observational.
For the patient with isolated PFO and a stroke or TIA,
support for the use of aspirin therapy is based on 2 studies:
(1) the French PFO-ASA study, which found that the risk of
recurrence was only 2.3% after 4 years as opposed to 4.2%
in the group with no patent foramen ovale or atrial septal
aneurysm, and (2) the PICSS study (Patent Foramen Ovale
in Cryptogenic Stroke Study), which did not demonstrate
a statistically significant diﬀerence between the eﬀects of
(325mg) and warfarin (INR 1.7 to 2.2) on the risk of
subsequent stroke or death among patients with cryptogenic
stroke and a PFO [127, 139, 140]. For those patients with
a PFO and ASA, the French PFO-ASA study found the
incidence of recurrent stroke with aspirin therapy to be
significantly higher at 15.2% and suggested that perhaps
warfarin or surgical options might be more beneficial in this
cohort [127]. The PICSS study, however, refuted this finding
[139]. Experts note that the PICSS study was primarily
designed as a prognostic study and was underpowered to
demonstrate a treatment eﬀect [140]. And for those patients
with an isolated ASA alone, the eﬃcacy of aspirin therapy
was demonstrated in the French PFO-ASA study in which
the 10 patients with isolated ASA did not have a recurrence
of events on aspirin therapy of 300mg/day [127]. In the
CODICIA study, 20.8% of patients received anticoagulant
treatment for the prevention of recurrence. The conclusions
of the CODICIA study are similar to the PICSS study:
anticoagulant treatment is not significantly superior to
antiplatelet therapy in the prevention of stroke recurrence.
Despite the tendency to a greater benefit of anticoagulation
in older patients with cryptogenic stroke, which was also
observed in the PICSS study, the results and design of the
CODICIA, PICSS, and WARSS studies do not justify its
prolonged use at the present time [137, 138, 141]. Stroke
associated with RLSh/PFO has a better functional prognosis
than cryptogenic stroke without RLSH/PFO. This is due
to the lesser volume of the infarct in patients with stroke
and RLSh in comparison with the volume of the infarct of
cryptogenic stroke without RLSh (14.3mL (1.5–35.4) versus
6.5mL (1.3–16.6)) and suggests that themechanism of stroke
in patients with and without RLSh/PFO is diﬀerent [142].
Surgical options to close a patent foramen ovale have
been oﬀered to patients with patent foramen ovale and a
history of stroke, especially when certain high-risk factors
are present [138, 140]. Three surgical options for closure
are available: (1) the traditional open thoracotomy foraminal
closure, (2)minimally invasive surgery, and (3) percutaneous
closure techniques [143]. The Randomized Evaluation of
Recurrent Stroke Comparing PFO Closure to Established
Current Standard of Care Treatment (RESPECT) trial, the
CLOSURE I trial, and the CardiaPFO trial are currently
comparing medical and percutaneous closure approaches,
but large patient enrolment would be necessary due to the
low event rate in these patients.
Currently, the evidence is insuﬃcient to determine if
OAC is superior to aspirin for the prevention of recurrent
stroke or death in patients with cryptogenic stroke and PFO,
or the value of surgical or endovascular closure. Current
recommendations are based mostly on expert opinion
pending the completion of ongoing randomized controlled
trials that are seeking to compare the various treatment
modalities [138, 140, 144, 145].
9. Endocarditis
9.1. Infective Endocarditis. Cerebral embolism is a common
complication of infectious endocarditis but accounted for
less than 1% of all causes of cerebral embolism in the Cere-
bral Embolism Stroke Registry [146, 147]. Despite markedly
changing risk factors, age range, and pathogenicmicroorgan-
isms, there remains a striking uniformity in the frequency
and distribution of neurologic problems associated with
infective endocarditis. Their importance is underscored by
the frequency with which they occur, the fact that they can be
the initial or predominant manifestation of the disease, and
that they have become a leading cause of disease mortality
now that infected heart valves can be surgically repaired or
replaced. In several series of patients described over a span
of 6 decades, approximately 30% of patients with infective
endocarditis had a neurologic complication, and for about
half of those, the neurologic event was the presenting clinical
symptom [148–153]. Though there has been an overall
decline of mortality in patients with infective endocarditis,
the morbidity from neurologic complications has remained
unchanged for years.
Cerebral embolism is the most common complication
occurring in 14% to 20% of patients with infective endo-
carditis. Cerebral emboli are considerably more common
in mitral valve endocarditis than in infection of the aortic
valve. About half of these emboli are multiple by neu-
roimaging studies. Conversion to hemorrhagic infarction
occurs spontaneously in less than 10% of these patients. In
developed countries, between 7% and 25% of all cases of
infective endocarditis involve prosthetic valves [154]. Data
pooled from multiple series of patients with prosthetic valve
endocarditis show a rate of CNS complications similar to
that of patients with native valve disease, provided that
anticoagulation was appropriately managed.
Neurologic manifestations of infectious endocarditis
mainly occur before antimicrobial treatment is begun, thus
reinforcing our belief that rapid diagnosis and initiation of
antimicrobial therapy may still be the most eﬀective means
to prevent neurologic complications [153]. The indications
for and risk of anticoagulation for endocarditis-associated
cerebral embolism continue to generate controversy. There
is no convincing evidence that prophylactic anticoagulant
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therapy reduces the incidence of emboli in native valve
endocarditis, and it is generally believed that the routine
use of anticoagulants is not justified [88]. It should nei-
ther be instaured after embolism occurs because the risk
of hemorrhage may be high. Patients with mechanical
prosthetic valves or AF who develop endocarditis usually
are continued on their anticoagulation [7]. However, the
risk of hemorrhage if embolism occurs is then high.
Anticoagulation should be withheld for at least 48 hours
in prosthetic valve patients suﬀering a cerebral embolism
with endocarditis. Patients with cardiogenic brain embolism
should be monitored for signs of deterioration that suggest
a hemorrhagic transformation, and a follow-up imaging
study in 1 to 2 weeks is advisable in order to rule out
abscess formation or evidence of a mycotic aneurysm
[155].
9.2. Nonbacterial Thrombotic Endocarditis. Nonbacterial
thrombotic endocarditis (NBTE) is reported most com-
monly in patients with adenocarcinoma, especially mucin-
producing carcinomas of the lung or gastrointestinal tract,
and lymphoma. The malignancy is usually widespread and
cerebral infarction is a late complication, but in rare instances
NBTE with cerebral infarction is the presenting sign of
cancer. The reported incidence of systemic embolism in
NBTE varies widely (14–91%, average 42%) [156]. NBTE
is more common in the aortic and mitral valves, but any
valve may be aﬀected. The pathogenesis of NBTE is not fully
understood, but the most important predisposing factors
appear to be an underlying coagulopathy, edema, degenera-
tion of valvular collagen, and the eﬀects of mucin-producing
carcinomas. Treatment of NBTE is directed toward control
of the underlying disease, in most instances neoplasia and/or
sepsis, and toward treatment of thromboembolism. The
most eﬀective agent is heparin, and little benefit has been
observed with vitamin K antagonists. Patients with NBTE
and systemic or pulmonary emboli should be treated with
full-dose unfractionated heparin IV or subcutaneous heparin
[88].
9.3. Libman-Sacks Endocarditis. Valvular involvement is the
most frequent form of heart disease in systemic lupus
erythematosus (SLE). Involvement includes valve masses
also known as Libman-Sacks vegetations, valve thickening,
valve regurgitation, and valve stenosis. On transesophageal
echocardiography, the prevalence of valvular disease in
SLE has been shown to be up to 60–74%. The incidence
of ischemic cerebrovascular stroke in patients with SLE
is 10–20%; in these patients, the existence of valvular
involvement and left heart thrombi was proven in 70–
90% of cases [157]. A frequent concomitant appearance
of valvulopathy, thromboembolic events (mostly stroke or
TIA), and antiphospholipid antibodies has been observed.
Ischemic manifestations, previously thought to be due
to vasculitis, are usually due to thrombotic or car-
dioembolic events. Because of the increased incidence of
stroke in SLE and the frequent valvulopathy in these
patients, prophylactic antiplatelet therapy may be con-
templated in all SLE patients. Anticoagulant treatment
should be considered independently of echocardiographic
results in patients who had cerebrovascular or systemic
embolic events with no features of systemic SLE vasculitis
[158].
10. Antithrombotic Therapy in Cardioembolic
Stroke in Special Situations
10.1. Immediate Anticoagulation after Acute
Cardioembolic Stroke
10.1.1. Acute Stroke. In a review of the Cochrane database
system [159] twenty-four trials involving 23,748 partic-
ipants with acute stroke were included. The anticoagu-
lants tested were standard unfractionated heparin, low-
molecular-weight heparins, heparinoids, oral anticoagulants,
and thrombin inhibitors. For the analysis of the primary
outcome, all of the data related to the initiation of antico-
agulants within 48 hours of onset, and 89% of the evidence
related to unfractionated heparin. Based on 11 trials (22,776
participants), there was no evidence that anticoagulant
therapy reduced the odds of death from all causes (OR,
1.05; 95% CI, 0.98 to 1.12) at the end of followup. Similarly,
based on 8 trials (22,125 participants), there was no evidence
that anticoagulants reduced the odds of being dead or
dependent at the end of followup (OR, 0.99; 95% CI, 0.93
to 1.04). Although anticoagulant therapy was associated
with fewer recurrent ischemic strokes (OR, 0.76; 95% CI,
0.65 to 0.88), it was also associated with an increase in
symptomatic intracranial hemorrhages (OR, 2.55; 95% CI,
1.95 to 3.33). Similarly, anticoagulants reduced the frequency
of pulmonary emboli (OR, 0.60; 95% CI, 0.44 to 0.81),
but this benefit was oﬀset by an increase in extracranial
hemorrhages (OR, 2.99; 95% CI, 2.24 to 3.99).
10.1.2. Acute Cardioembolic Stroke. Paciaroni et al. [160]
identified randomized trials comparing anticoagulants
(unfractionated heparin or low-molecular-weight heparin or
heparinoids), started within 48 hours, with other treatments
(aspirin or placebo) in patients with acute ischemic car-
dioembolic stroke. Seven trials, involving 4624 patients with
acute cardioembolic stroke, met the criteria for inclusion.
All studies included patients with cardioembolic ischemic
stroke (n = 4624) randomized within 48 hours from
stroke onset. Atrial fibrillation was present in 3797 patients
and other mixed cardioembolic sources in 827. Three trials
used UFH [161–163], 3 trials LMWH (TAIST tinzaparin,
HAEST dalteparin, and FISS-bis nadroparin) [164–166],
and one trial (TOAST) heparinoid (danaparoid) [167]. In
the CESG (Cerebral Embolism Study Group) trial, the
followup was reported only at 14 days [166]. Compared
with other treatments, anticoagulants were associated with a
nonsignificant reduction in recurrent ischemic stroke within
7 to 14 days (3.0% versus 4.9%, odds ratio 0.68, 95% CI: 0.44
to 1.06, P = .09, number needed to treat = 53), a significant
increase in symptomatic intracranial bleeding (2.5% versus
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0.7%, odds ratio 2.89; 95% CI: 1.19 to 7.01, P = .02, number
needed to harm = 55), and a similar rate of death or disability
at final followup (73.5% versus 73.8%, odds ratio 1.01; 95%
CI: 0.82 to 1.24, P = .9).
In the single study in which anticoagulation was started
within 3 hours from stroke onset, death or disability was
reduced by anticoagulant treatment. These results should be
interpreted with caution because other trials did subgroup
analyses in hyperacute patients and showed neutral results.
Several studies have suggested that besides its antithrombotic
eﬀects, UFH also modulates inflammation [168–172]. Thus,
the positive eﬀect of early heparin could be the result of
either its antithrombotic eﬀects and/or its modulation on
the anti-inflammatory pathway that appears relevant in the
first hours. Whatever the mechanism for improvement, the
benefit observed in patients treated within 3 hours suggests
the need for further trials on the eﬃcacy of very early
administration of anticoagulants in acute cardioembolic
stroke. In selecting the study population for these trials, size
of ischemia, age, and blood pressure in the acute phase, all
known as risk factors for hemorrhagic complications, should
be considered.
10.1.3. Acute Stroke with AF. Hart et al. presented [173] a
critical review of 3 randomized clinical trials testing aspirin,
heparin/heparinoid, or both involving 5029 patients with
AF and acute stroke. In the International Stroke Trial (IST),
19,435 patients with suspected acute ischemic stroke within
48 hours (93% confirmed as ischemic by early CT) were
randomly assigned to aspirin 300mg/d versus no aspirin
and, separately, to 1 of 2 dosages of subcutaneous heparin
versus no heparin in a 2× 3 factorial design [174]. Treatment
was not masked, and there were no prespecified criteria
for early recurrent stroke. Results for the subgroup of 3169
participants (17%) with AF have been reported. The Chinese
Acute Stroke Trial (CAST) compared aspirin 160mg/d with
placebo (double-blind) in 21,106 patients with suspected
acute ischemic stroke within 48 hours. AF was present in
only 7% (n = 1411) of participants. Limited data about the
subgroup of AF patients from the CAST have been published
[175], with additional outcome data available combining AF
patients assigned to aspirin in the CAST with those from the
IST. The Heparin in Acute Embolic Stroke Trial (HAEST)
randomly assigned 449 AF patients with acute ischemic
stroke (all confirmed by CT) within 30 hours of stroke
onset from 45 Norwegian centers to a low-molecular-weight
heparin (dalteparin 100 IU/kg SC twice daily) or aspirin
160mg/d in a double-blind design, with the main outcomes
of recurrent stroke during the first 14 days and functional
status or death after 3months [176]. Early recurrent ischemic
stroke occurred in about 5% of patients during the 2
to 4 weeks after initial stroke. Data from the 2 relevant
randomized clinical trials conflict. The double-blind HAEST
found no reduction in early recurrent ischemic stroke among
AF patients randomized to receive a low-molecular-weight
heparin versus aspirin [176]. In contrast, the IST found “a
clear and dose-dependent reduction in recurrent ischemic
stroke among patients allocated to heparin” (P = .001) given
subcutaneously [177]. The overall rates of recurrent ischemic
stroke in the control arms (5% in IST, 8% in HAEST) and
of secondary brain hemorrhage (2% in IST, 3% in HAEST)
among those given heparin/heparinoid were similar in the
2 trials. However, the reduction in early recurrent ischemic
stroke by heparin in the IST was almost entirely oﬀset
by increased symptomatic brain hemorrhage. Data conflict
about whether early use of heparin/heparinoid reduced early
recurrent ischemic stroke but are consistent regarding its
lack of overall benefit on long-term functional outcome.
Modest benefits for reduction of early recurrent stroke and
functional outcome were associated with aspirin use, based
largely on subgroup analysis from a single, large, unblinded
trial.
10.1.4. When to Start Anticoagulation after a Cardioembolic
Stroke for Secondary Prevention?
Subcutaneous unfractionated heparin (UFH) at low or
moderate doses [174], nadroparin [178, 179], certoparin
[180], tinzaparin [181], dalteparin [176], and intravenous
danaparoid [182] have failed to show an overall benefit of
anticoagulation when initiated within 24 to 48 hours from
stroke onset. Improvements in outcome or reductions in
stroke recurrence rates were mostly counterbalanced by an
increased number of hemorrhagic complications. In a meta-
analysis of 22 trials, anticoagulant therapy was associated
with about nine fewer recurrent ischaemic strokes per 1000
patients treated (OR 0.76; 95%CI 0.65–0.88), and with about
nine more symptomatic intracranial hemorrhages per 1000
(OR 2.52; 95% CI 1.92–3.30) [183]. However, the quality of
the trials varied considerably. On the basis of the usual timing
of secondary hemorrhagic transformation between 12 hours
and 4 days after stroke onset, it seems reasonable to begin
warfarin as soon as the patient is medically and neurologi-
cally stable, often 2 to 3 days after stroke, to achieve thera-
peutic anticoagulation 7 to 10 days after stroke onset. Some
experts routinely repeat a CT scan before initiating warfarin
and delay warfarin therapy if hemorrhagic transformation is
evident. Minor degrees of hemorrhagic transformation are
frequent (particularly on MRI), and the clinical significance
regarding initiation of warfarin is unclear and controversial.
No benefit of heparin has been demonstrated for acute
stroke patients with AF; whether selected subgroups would
respond diﬀerently remains to be proven. Aspirin followed
by early initiation of warfarin for long-term secondary
prevention is a reasonable antithrombotic management. Few
clinical trials have assessed the risk-benefit ratio of very
early administration of UFH in acute ischaemic stroke. In
one study, patients with nonlacunar stroke anticoagulated
within 3 hours had more self-independence (38.9% versus
28.6%; P = .025), fewer deaths (16.8% versus 21.9%;
P = .189), and more symptomatic brain hemorrhages
(6.2% versus 1.4%; P = .008) [184]. In the RAPID (Rapid
Anticoagulation Prevents Ischemic Damage) trial, patients
allocated UFH had fewer early recurrent strokes and a similar
incidence of serious hemorrhagic events, compared with
those receiving aspirin [185]. In the UFH group, ischaemic
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or hemorrhagic worsening was associated with inadequate
plasma levels of UFH. In view of these findings, the value
of UFH administered shortly after symptom onset is still
debated [186, 187].
10.2. Embolic Events during Adequate Antithrombotic Therapy.
In the patient who has a definite embolic episode while
undergoing adequate antithrombotic therapy or INR is in
range, the dosage of antithrombotic therapy should be
increased, when clinically safe, as follows: (i)warfarin, INR
2.0 to 3.0: warfarin dose increased to achieve INR of 2.5
to 3.5; (ii)warfarin, INR 2.5 to 3.5: warfarin dose may
need to be increased to achieve INR of 3.5 to 4.5; (iii)not
taking aspirin: aspirin 75 to 100mg per day should be
initiated; (iv)warfarin plus aspirin 75 to 100mg per day:
aspirin dose may also need to be increased to 325mg
per day if the higher dose of warfarin is not achieving
the desired clinical result; (v)aspirin alone: aspirin dose
may need to be increased to 325mg per day, clopidogrel
75mg per day per day added, and/or warfarin added [89].
However, there is class IA recommendation for European
Stroke Organization not to use double antiplatelets except
on special occasions like, for example, unstable angina,
non-Q myocardial infarction, and after stent. When INR
is in range new anticoagulants, can be used. Dabigatran
is currently only approved in USA and Japan. Its use can
be extended to situations of hypersensibility, resistance or
intolerance to classic anticoagulants and diﬃculty in daily
control.
10.3. Long-Term Secondary Stroke Prevention after OAC-
Related ICH. Another diﬃcult decision in clinical practice is
whether anticoagulants should be restarted and maintained
indefinitely in patients with a history of OAC-related ICH
and at risk of cardioembolic events. Stroke prevention in
this situation needs to balance the risk/benefit of diﬀerent
antithrombotic options and the estimated risk of intracranial
bleeding recurrence. To this aim, an important step is to
establish the most likely cause of the bleeding. Whereas
hypertensive vasculopathy appears to be the most important
mechanism for ICH in deep hemispheric regions of the
brain, cerebral amyloid angiopathy may be the most com-
mon underlying pathophysiology for lobar ICH. The risk of
recurrent hypertensive ICH can be decreased by an adequate
control of hypertension [188] whereas cerebral amyloid
angiopathy lacks any known treatment. In a prospective
study of elderly patients who survived lobar ICH, recurrent
ICH occurred in 22% at 2 years [189]. The rate of recurrent
ICH in survivors of deep hemispheric ICH was estimated
to be 2.1% per patient-year [190]. Therefore, in patients
with lobar hemorrhage and major sources of embolism,
decision analysis models based on retrospective data suggest
that the strategy of “do not anticoagulate” appears robust
[190]. Contrarily, the risks and benefits of anticoagulation
are more closely balanced when applied to patients with
deep hemispheric ICH. In the latter case, OAC might
be justified if the estimated risk of ischemic stroke is
high.
10.4. Pregnancy. Pregnancy increases the likelihood of cere-
bral infarction to approximately 10-times that of the
expected incidence in nonpregnant young women [191].
Cardioemboli are responsible for the majority of ischemic
infarctions of arterial origin during pregnancy. Most strokes
during pregnancy aﬀect the anterior circulation, especially
the middle cerebral artery. Cardiac conditions frequently
associated with cerebral embolism during pregnancy include
atrial arrhythmias, congenital disorders (e.g., atrial septal
defects), and acquired disorders (e.g., peripartum cardiomy-
opathy). Venous infarction also occurs in the peripartum
period [191].
The consequences of atrial fibrillation during pregnancy
are potentially life-threatening. Atrial fibrillation may be
chronic as a consequence of rheumatic mitral stenosis or it
may develop de novo during the course of the pregnancy.
Congestive heart failure occurs more frequently with de novo
atrial fibrillation during pregnancy than with chronic atrial
fibrillation [191]. Women with chronic atrial fibrillation
or valve prosthesis who are treated with warfarin should
take contraceptive precautions to avoid exposing the fetus
to the potential teratogenic eﬀect of warfarin. Warfarin
(vitamin K antagonist therapy) crosses the placenta and has
been associated with an increased incidence of spontaneous
abortion, prematurity, and stillbirth. Warfarin can also cause
bleeding in the fetus and embryopathy, consisting of nasal
hypoplasia and/or stippled epiphyses after in utero exposure
during the first trimester of pregnancy, and central nervous
system abnormalities after exposure during any trimestre.
Several studies suggest that UFH or LMWH therapy is safe
for the fetus [192–196]. Heparin does not cross the placenta
and does not have the potential to cause fetal bleeding
or teratogenicity. However, bleeding at the uteroplacental
junction is possible, and numerous case series and patient
registries attest to a high incidence of thromboembolic
complications (12% to 24). If pregnancy is desired, alterna-
tive anticoagulation methods such as subcutaneous heparin
should be implemented prior to conception and continued
through the first trimester. Dipyridamole should not be
considered as an alternative antiplatelet agent because of its
harmful eﬀects on the fetus. Neither warfarin nor heparin
is contraindicated in postpartum mothers who breast-feed
[197].
11. Bleeding Risk in Orally
Anticoagulated Patients
The risk of major bleeding in patients receiving OAC is 3%
per year; and approximately 20% of major bleeding events
are fatal [198]. Even at safe anticoagulant levels (INR 2.0
to 3.0) annual rates of major, life threatening, and fatal
bleeding are 2%, 1%, and 0.25%, respectively [199]. Every
one-point rise in INR increases the risk of major bleeding
by 42% [200], and the interval 2.0–2.5 gives the lowest risk
of stroke and death in patients with nonvalvular AF [201].
Concomitant hypertension, prior cerebrovascular accident,
gastrointestinal bleeding or anticoagulation-related bleeding,
use of aspirin or nonsteroidal anti-inflammatory drugs, older
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age, patient reliability, and the interactions of OAC with
other medications contribute to the risk of bleeding [202].
The most frequent complication of OAC is gastroin-
testinal bleeding, but intracranial hemorrhage (ICH) is the
main cause of fatal bleeding. In a pooled analysis of the
first five trials with warfarin in patients with AF, the annual
rate of OAC-related ICH was 0.3% [203]. OAC-related ICH
occurs at a rate of 2 to 9 per 100,000 population/year, an
incidence which is 7- to 10-fold higher than in patients
not receiving OAC [204]. The incidence of intracranial
hemorrhage due to OAC is increasing, probably because
of the larger number of elderly patients that receive this
treatment, the association with aspirin, or the expanded use
of OAC for stroke prevention [205].
12. New Treatment Strategies and
New Anticoagulants
Anticoagulation therapy’s associated risk of hemorrhage
and cumbersome monitoring requirements have encouraged
the investigation of alternative therapies for individuals
with atrial fibrillation. For example, indobufen, a reversible
inhibitor of platelet cyclooxygenase activity, was evaluated in
the SIFA trail. The SIFA trial was a prospective, randomized,
open study involving a total of 916 patients with nonvalvular
AF and a recent cerebral ischemic episode. Patients received
either indobufen (100 or 200mg BID) or warfarin (INR 2.0
to 3.5) for 12 months. The combined incidence of nonfatal
stroke (including intracerebral bleeding), pulmonary or
systemic embolism, nonfatal myocardial infarction, and
vascular death was not significantly diﬀerent between the two
treatment groups [206]. However, the limited power of the
study did not exclude the existence of substantial diﬀerences
between the two treatments. Data from the AMADEUS
trial, which compared the long-acting, parenteral factor
Xa inhibitor, idraparinux, with warfarin, showed that the
idraparinux arm had lower rates of stroke and systemic
embolism (idraparinux 0.9% versus warfarin 1.3%, P =
.007) and was not inferior to warfarin [207]. However,
idraparinux had a significantly higher rate of bleeding than
warfarin (19.7% versus 11.3%, P < .0001), especially in
patients with advanced age and renal insuﬃciency. The
BOREALIS-AF study will compare the renal dose-adjusted,
biotinylated idraparinux with warfarin in patients with atrial
fibrillation. Other oral factor Xa inhibitors being tested for
stroke prevention in patients with atrial fibrillation in phase
III clinical trials include rivaroxaban in the ROCKET-AF trial
[208] and apixaban in the ARISTOTLE trial.
Patients undergoing major orthopedic surgery have an
elevated risk of venous thromboembolism (VTE). As a result,
it has become standard practice that patients undergoing
major orthopedic surgery receive thromboprophylaxis with
an anticoagulant. Dabigatran etexilate and rivaroxaban,
direct thrombin inhibitors, are anticoagulants that have been
approved for the prevention of VTE in patients who have
undergone elective total hip replacement (THR) or total knee
replacement (TKR). A review from the Canadian Agency
for Drugs and Technologies in Health [209] analysed the
clinical eﬀectiveness and safety of dabigatran or rivaroxa-
ban compared to low-molecular-weight heparins (LMWH),
unfractionated heparin, warfarin, or fondaparinux for
thromboprophylaxis after elective total hip replacement,
elective total knee replacement, or hip fracture surgery. The
studies showed no statistically significant diﬀerences between
dabigatran and enoxaparin in any of the endpoints with
comparable side eﬀects and superior clinical-eﬀectiveness of
rivaroxaban 10mg once daily compared to enoxaparin 40mg
once daily with similar side eﬀects. However, patients with
severe renal insuﬃciency, severe liver disease, or at high risk
of bleeding were excluded from the reviewed trials [209].
Table 5 shows a comparison of diﬀerent anticoagulants
available [210–217].
Although their first application in clinical practice
occurred in the 1940s, vitamin K antagonists remain the
only form of oral anticoagulant medication approved for
long-term use in stroke prevention. Vitamin K antagonists
are highly eﬀective for the prevention and/or treatment
of most thrombotic disease, the significant interpatient
and intrapatient variability in dose-response, the narrow
therapeutic index, and the numerous drug and dietary
interactions associated with these agents have led clinicians,
patients, and investigators to search for alternative agents.
Novel anticoagulant medications are being studied for the
prevention and treatment of venous thromboembolism, the
treatment of acute coronary syndromes, and the prevention
of stroke in patients with atrial fibrillation [218]. The direct
thrombin inhibitor, dabigatran etexilate, has shown eﬃcacy
over warfarin in a recent trial for the prevention of stroke
associated with AF. Rivaroxaban and apixaban are in the
late stages of development and several others as edoxaban,
the parenteral factor Xa inhibitor, idrabiotaparinux, or the
novel VKA, tecarfarin, are currently being assessed [219].
The majority of these new anticoagulants are thrombin
direct inhibitors which inhibit the conversion of fibrinogen
to insoluble fibrin by thrombin, binding only to the active
site of thrombin and do it reversibly, inhibiting not only
free thrombin but also clot-bound thrombin. They exibit
stable pharmacokinetics obviating the need for coagulation
monitoring or dose titration, and lack clinically significant
food or drug interaction. Moreover they oﬀer other potential
that includes fixed oncedaily dosing, oral administration and
rapid onset of action. However, there are several concerns
regarding potential harm from using dabigatran and rivarox-
aban, including an increased risk for hepatotoxicity, clinically
significant bleeding, and acute coronary events.
Ximelagatran, another direct thrombin inhibitor, was
also explored in patients with AF. Two long-term studies,
SPORTIF III and IV [220] (Stroke Prevention using an
Oral Thrombin Inhibitor in Nonvalvular Atrial Fibrillation
III (open label) and V (double-blind)) were conducted,
assessing the safety and eﬃcacy of fixed-dose ximelagatran
(36mg twice daily) compared to dose-adjusted warfarin
(INR 2.0-3.0) [220, 221]. Primary events occurred in 2.3%
of patients taking warfarin and in 1.6% in the ximelagatran
group (P = .1). The rates of combined minor and major
hemorrhages were lower with ximelagatran (29.8% versus
25%; relative risk reduction 14%; P = .007) [220]. The risk
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Table 5: Comparison of anticoagulants. APPC: activated prothrombin complex concentrate; CYP3A4: cytochrome P450 enzyme 3A4;
FFP: fresh frozen plasma; HIT: heparin-induced thrombocytopenia; Iv: intravenous; IU: international units; LMWH: low-molecular-weight
heparins; PCC: prothrombin complex concentrate; P-gp: P-glycoprotein; rFVIIa: recombinant activated factor VII; Sc: subcutaneous; UFH:
unfractioned heparins; ∗all should be used with caution with other anticoagulants, nonsteroid anti-inflammatory drugs, thrombolytics, or
platelet inhibitors because of an increased risk of bleeding. ∗∗ Time to reach peak plasma concentrations and half-life elimination may be
delayed after surgery; from [196–204].
Parameter Dabigatran Rivaroxaban
LMWH
UFH Warfarin
Enoxaparin Dalteparin
Routine coagulation
monitoring required
No No No Al inicio Yes
Use with renal
insuﬃciency
Moderate: dosage
adjustment (150mg
daily)
Moderate:
use caution
Moderate:
use caution
Moderate: yes
Moderate: use
caution
Severe:
contraindicated
Severe: not
recommended
Severe: dosage
adjustment
Severe: use
caution
Severe: use
caution
Use with hepatic
insuﬃciency
Not recommended Contraindicated Use caution Use caution Use caution
Potential for HIT No No Low High No
Drug interactions∗
Quinidine,
amiodarone,
antacids, potent P-gp
inhibitors (e.g.,
verapamil,
clarithromycin)
Potent inhibitors of
CYP3A4 and P-gp
(e.g., ketoconazole,
itraconazole,
ritonavir,
rifampicin). Strong
CYP3A4 inducers
(e.g., phenytoin,
carbamazepine)
No clinically significant
drug interactions known
No clinically
significant drug
interactions
known
Multiple drugs
Reversal of
anticoagulant eﬀect
rFVIIa, APCC (in
rats) [35]
rFVIIa, APCC (in rats
and primates)
[36, 37]
Protamine sulfate
(partial)
Protamine
sulfate
Vitamin K, FFP,
PPC
Target
Factor Iia (thrombin)
direct
Factor Xa direct
Factor Xa and IIa
(thrombin) indirect
Antithrombin
III
Vitamin K
epoxide
reductase
Route Oral Oral Sc Iv or Sc Oral
Peak plasma levels
(healthy volunteers)∗∗
0.5 to 2 hours. After
surgery: 7 to 9 hours
2 to 4 hours 3 to 5 hours 4 hours 1 to 3 hours
4 hours
Therapeutic
eﬀect in 5 to 7
days
Half-life elimination∗∗ 11 5 to 9 4 to 7 3 to 4 1 to 2 20 to 60
after surgery: 14 to 17 after surgery: 7 to 11
Dosing for
thromboprophylaxis after
orthopedic surgery
Initial: 110mg Initial: 10mg 30mg twice
daily
5,000 IU
daily
5,000 units
every 8 to 12
hours
Individualized
once daily based
on target INR 2.5
Maintenance: 220mg
once daily
Maintenance:
10mg once daily
of intracranial hemorrhage was 0.19% per year for warfarin
and 0.11% per year in ximelagatran, and the annual rates of
ischemic strokes were 1.46% and 1.37%, respectively. Major
bleeding occurred at an annual rate of 2.5% in the warfarin-
treated group, and 1.9% in the ximelagatran-treated group,
a nonsignificant diﬀerence. The majority of ischemic strokes
were noncardioembolic in origin, typically lacunar or large-
artery atherosclerosis-related strokes. However, in 6.1% of
patients receiving ximelagatran, there was an increase in
alanine aminotransferase greater than 3-times the upper
limit of normal. In the SPORTIF V trial [221], (a double-
blind trial involving relatively high-risk patients with nonva-
lvular AF), ximelagatran was not inferior to well-controlled
warfarin within the prespecified margin of 2.0% per year
for prevention of stroke and systemic embolism. However,
3 deaths with liver failure were reported in the trials, and
it was estimated 1 death from hepatic failure among 2300
patients treated [222]. In data presented to the Food and
Drug Administration (FDA) on all patients receiving long-
term ximelagatran, an increase in alanine aminotransferase
>3x normal occurred in 7.9% of patients compared with
1.2% of patients receiving comparator therapy, leading the
FDA to deny approval of ximelagatran because of concerns
about hepatotoxicity [223]. Later on, the sponsor oﬃcially
notified the Committee for Medicinal products for Human
Use that it wished to withdraw its application for a marketing
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authorization for ximelagatran for the prevention of stroke
associated with AF.
In the RE-LY trial (Randomized Evaluation of Long-
Term Anticoagulation Therapy) two fixed doses of dabi-
gatran (110mg or 150mg, twice daily) administered in a
blindedmanner were compared to open-label use of warfarin
in 18,113 patients with AF [224]. The primary outcome
measure was stroke or systemic embolism, and the primary
safety outcome was major hemorrhage. Stroke or systemic
embolism occurred in 1.53% per year in patients receiving
110mg of dabigatran, 1.11% per year with 150mg dabi-
gatran, and 1.69% per year in patients receiving warfarin,
with a median duration of followup of 2.0 years [221]. Both
doses were noninferior to warfarin, and the 150mg dose
was shown to be superior to warfarin (RR 0.66, 95% CI
0.53 to 0.82). Hemorrhagic stroke happened in 0.38% per
year with warfarin, 0.12% per year with 110 mg dabigatran,
and 0.10% per year with 150mg dabigatran. Only major
gastrointestinal bleeding was more frequent in patients
taking 150mg dabigatran in comparison to warfarin. In this
study, there were no significant increases in liver enzymes
with dabigatran [224]. The only adverse event that was more
frequent with dabigatran was dyspepsia. The conclusion of
this trial was that both doses of dabigatran were noninferior
to warfarin in the prevention of stroke or systemic embolism.
Moreover, the dose of 150 mg was superior to warfarin for
embolic prevention, and the dose of 110 mg produced less
hemorrhagic events. Therefore, the authors suggested that
the dose of dabigatran could potentially be tailored to take
into consideration the risk characteristics of a specific patient
[224]. Nevertheless, it has to be taken in consideration that
the number of patients needed to be treated with dabigatran
at a dose of 150mg to prevent one nonhemorrhagic stroke,
in comparison to warfarin, is approximately 357 [225]. For
this reason and due to a greater risk of nonhemorrhagic
side eﬀects and a twice-daily dosing, some authors think
that switching to dabigatran would not be of great value in
patients on warfarin with a good INR control [225].
BBC News online published on 2008 that dabigatran will
cost the NHS $4.20 per day, which is equivalent to several
other anticoagulants [226], but more than ten-times the
cost of warfarin. The total cost of warfarin use includes not
just the cost of the actual medication, but also the time
and cost of INR monitoring, which is not required with
dabigatran. Dabigatran is currently approved in the USA,
Canada and Japan and probably others will follow in the very
near future. Its clear benefit over warfarin prompted that in
many countries it is already introduced in daily practice with
patients, informed consent. Failure of warfarin treatment,
recurrent stroke or TIA, and poor adherence to standard
treatment are some of the indications for use of this new
anticoagulant.
ROCKET AF is a randomized, double-blind, double-
dummy, event-driven trial, which aims to establish the
noninferiority of rivaroxaban compared with warfarin in
patients with nonvalvular AF who have a history of stroke
or at least 2 additional independent risk factors for future
stroke. Patients are randomly assigned to receive rivaroxaban,
20mg once daily (od), or dose-adjusted warfarin titrated
to a target international normalized ratio (INR) of 2.5
(range 2.0-3.0, inclusive) using point-of-care INR devices
to receive true or sham INR values, depending on the
study drug allocation. The primary eﬃcacy endpoint is
a composite of all-cause stroke and noncentral nervous
system systemic embolism. The primary safety endpoint is
the composite of major and clinically relevant nonmajor
bleeding events. Over 14,000 patients have been randomized
at 1,100 sites across 45 countries, and will be followed until
405 primary outcome events are observed. The ROCKET
AF study aims to determine the eﬃcacy and safety of
rivaroxaban as an alternative to warfarin for the prevention
of thromboembolism in patients with AF [227].
Although some eﬃcacy and safety data for dabigatran
and rivaroxaban are available, data from additional trials
and postmarketing surveillance will be needed. Alterations
of rivaroxaban and apixaban pharmacokinetics upon inter-
actions with inhibitors and inducers of CYP3A4 or P-
glycoprotein may complicate the use of these compounds
in daily practice whereas dabigatran elimination largely
depends on renal function.
Apart from pharmacological therapy for atrial fibrilla-
tion, a broad range of surgical approaches are emerging.
Traditional surgical treatment of atrial fibrillations includes
the Cox-Maze III procedure [228]. New surgical approaches
include alternate energy sources (radiofrequency, microwave,
and cryothermy) and simplified left atrial lesion sets.
These operations cure atrial fibrillation in 70% to 80% of
patients. Percutaneous left atrial appendage transcatheter
occlusion (PLAATO) is an endovascular approach that
is being tested for prevention of embolism in high-risk
patients with atrial fibrillation who have a contraindica-
tion to anticoagulation therapy [229]. Whether mechan-
ical measures to prevent thromboembolism prove to be
as eﬀective and safe as anticoagulation remains to be
proven.
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